kidney injury. In a study of vancomycin compared with another antimicrobial for the treatment of MRSA infections in inpatients, suppose that a researcher used a propensity score analysis. The inclusion of length of hospital stay in the propensity score would adjust away the effect on the cost of vancomycin, resulting in increased length of hospital stay.

In the study by Klein et al., adjustment for potential mediators in the propensity score analysis leads to an analysis of the outcome of which is the extent to which MRSA infection, compared with MSSA infection, leads to increased or decreased healthcare costs not associated with length of stay, need for procedures, or severity of illness. However, we do not believe that this was the authors’ intent.

The presence of confounders of these intermediate variables (such as baseline comorbidities and their effect on both MRSA risk as well as length of stay) further complicates the analysis; a recent review discusses analytic methods for the problem of confounded intermediates [8].

We would be curious to see the results of an analysis that excludes from the propensity score derivation potential mediators of cost such as increased length of stay and increased number of procedures.

Notes

Financial support. M. Z. D. acknowledges support from the National Institutes of Health (grant 1R01AI139188).

Potential conflicts of interest. M. Z. D. reports grants from GlaxoSmithKline and personal fees from Baxter, outside the submitted work. Both authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.

Vagish Hemmige and Michael Z. David

1Division of Infectious Diseases, Albert Einstein College of Medicine, Bronx, New York; and 2Division of Infectious Diseases, Department of Medicine, University of Pennsylvania, Philadelphia

References

1. Klein EY, Jiang W, Mojica N, et al. National costs associated with methicillin-susceptible and methicillin-resistant Staphylococcus aureus hospitalizations in the United States, 2010–2014. Clin Infect Dis 2019; 68:22–8.
2. Roth JA, Juchler F, Widmer AE, Battegay M. Plea for standardized reporting and justification of propensity score methods. Clin Infect Dis 2019; 68:710–1.
3. Matsui K, Goldman L, Johnson PA, Kuntz KM, Cook EF, Lee TH. Comorbidity as a correlate of length of stay for hospitalized patients with acute chest pain. J Gen Intern Med 1996; 11:262–8.
4. Fine MJ, Pratt HM, Obrosky DS, et al. Relation between length of hospital stay and costs of care for patients with community-acquired pneumonia. Am J Med 2000; 109:378–85.
5. Taberi PA, Butz DA, Greenfield LJ. Length of stay has minimal impact on the cost of hospital admission. J Am Coll Surg 2000; 190:123–30.
6. Corrani P, Olsen M, Pedersen L, Dekkers OM, Vandenbroucke JP. Effect modification, interaction and mediation: an overview of theoretical insights for clinical investigators. Clin Epidemiol 2017; 9:331–8.
7. Greenland S, Pearl J, Robins JM. Causal diagrams for epidemiologic research. Epidemiology 1999; 10:37–48.
8. Richiardi L, Bellocco R, Zugna D. Mediation analysis in epidemiology: methods, interpretation and bias. International Journal of Epidemiology 2013;42(5):1511–9. doi: 10.1093/ije/dyt127.

Correspondence: V. Hemmige, Division of Infectious Diseases, Department of Medicine, Albert Einstein College of Medicine, 3400 Wayne Avenue, Suite 4H, Bronx, NY 10467 (vhemmige@montefiore.org).
them in the match, as *S. aureus* infections are more likely to be attributed to invasive procedures than they are to cause additional procedures [5–7].

To assess the implications of these decisions, we reanalyzed the data for 2014, excluding LOS and procedures from the matching process. In addition, we included data for 2015 and 2016 to assess trends since 2014. We found that the results from the original paper [3], that MSSA infections might be more costly in 2014, continued in 2015 and 2016 (Figure 1A). Removing LOS and procedures from the PSM algorithm resulted in an increase in the magnitude of this difference for pneumonia and other infections, though septicemia remained unchanged (Figure 1B). Restricting the analysis to patients who were discharged alive with an LOS \( \leq 10 \) days found the results of including LOS and procedures in matching (Figure 1C) were similar to the results when excluding LOS and procedures (Figure 1D). The impact of MRSA infections on LOSs has been estimated to be between 2 to 8 excess days of hospitalization, depending on the type of infection [8, 9]; thus, there is

![Figure 1](image-url)

**Figure 1.** Comparison of different propensity score analyses of the excess cost of MRSA compared to MSSA hospitalizations by infection type, 2014–2016. The excess cost of MRSA-related hospitalizations, compared to MSSA-related hospitalizations, was measured as the mean cost of MRSA-related hospitalizations minus the mean cost of MSSA-related hospitalizations. The error bars are the 95% confidence intervals of the difference in the means, and negative values indicate that MRSA-related hospitalizations were, on average, less costly than similar MSSA-related hospitalizations. **A**, Estimated costs using a PSM algorithm accounting for LOS and numbers of procedures for 2014 (same as in the original paper) through 2016. **B**, Estimated cost without LOS and numbers of procedures in a PSM algorithm. **C**, Estimated costs for patients that were discharged alive with an LOS \( \leq 10 \) days using a PSM algorithm including LOS and procedures for 2014 (same as in the original paper) through 2016. **D**, Estimated costs without LOS and number of procedures in a PSM algorithm for patients with an LOS \( \leq 10 \). LOS was stratified as 0–7, 8–14, 15–20, and 21+ days to account for the endogeneity of infection risk in longer lengths of stay. Abbreviations: LOS, length of stay; MRSA, methicillin-resistant *Staphylococcus aureus*; MSSA, methicillin-susceptible *Staphylococcus aureus*; PSM, propensity score matching; *S. aureus*, *Staphylococcus aureus*.
likely a causal relationship, as suggested by Hemmige and David [4]. However, not accounting for the endogeneity of infection risks related to longer lengths of stay, as we did when we stratified LOS, likely biases the results. Our findings point out the importance of taking into account the potential causal pathways in defining covariates for matching, but also highlight the difficulties in defining causal pathways in complicated hospital stays. These results also highlight the trade-off in using big data sets in health care, which are more generalizable but may not be able to account for some granular aspects of patient care. Nevertheless, the larger implication of our study, specifically the relative costliness of MSSA infections, remains true at a national level, regardless of methodology.

Notes

Financial support. This work was supported by the Bill & Melinda Gates Foundation (grant number OPP1113235).

Potential conflicts of interest. S. E. C. reports personal fees from Theravance and Novartis outside the submitted work. All other authors report no potential conflicts. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.

Eili Y. Klein,1,2∗ Katie K. Tseng,3 Oliver Gatalo,1 and Sara E Cosgrove1

1Department of Emergency Medicine, Johns Hopkins School of Medicine, and Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland; 2Center for Disease Dynamics, Economics & Policy, Washington, DC; and 3Division of Infectious Diseases, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland

Correspondence: E. Y. Klein, Department of Emergency Medicine, Johns Hopkins University, 5801 Smith Ave, Davis Suite 3220, Baltimore, MD 21229 (eklein@jh.edu).

Clinical Infectious Diseases® 2019;69(11):2040–2

© The Author(s) 2019. Published by Oxford University Press for the Infectious Diseases Society of America.

References

1. Kourtis AP, Hatfield K, Baggs J, et al. Vital signs: epidemiology and recent trends in methillin-resistant and in methillin-susceptible Staphylococcus aureus bloodstream infections — United States. MMWR Morb Mortal Wkly Rep 2019;68:214–9. Available at: http://www.cdc.gov/mmwr/volumes/68/wk/mm6809e1.htm?s_cid=mm6809e1_w

2. Klein EY, Mojica N, Jiang W, Cosgrove, SE, Septimus E, Morgan DJ, Laxminarayan R. Trends in methillin-resistant Staphylococcus aureus hospitalizations in the United States, 2010–2014. Clin Infect Dis 2017; 65:1921–3. doi:10.1093/cid/cix640

3. Klein EY, Jiang W, Mojica N, Tseng KK, McNell R, Cosgrove SE, Perl TM. National costs associated with methicillin-susceptible and methicillin-resistant Staphylococcus aureus hospitalizations in the United States, 2010–2014. Clin Infect Dis 2019; 68:222–8. doi:10.1093/cid/cyz399

4. Hemmige V, David MZ. Effects of including variables such as length of stay in a propensity score analysis with costs as outcome. Clin Infect Dis 2019; 69:2039–40.

5. Collins AS. Preventing health care-associated infections. Available at: https://www.ncbi.nlm.nih.gov/books/NBK2683

6. Asensio A, Guerrero A, Quereda C, Lízán M, Martínez-Ferrer M. Colonization and infection with methicillin-resistant Staphylococcus aureus: associated factors and eradication. Infect Control Hosp Epidemiol 1996; 17:20–8.

7. Pittet D, Tarara D, Wenzel RP. Nosocomial bloodstream infection in critically ill patients. Excess length of stay, extra costs, and attributable mortality. JAMA 1994; 271:1598–601.

8. Andreasen AES, Jacobsen CM, de Blasio B, White R, Kristiansen IS, Elstrom P. The impact of methicillin-resistant S. aureus on length of stay, readmissions and costs: a register based case-control study of patients hospitalized in Norway. Antimicrob Resist Infect Control 2017; 6:74. Available at: http://aricjournal.biomedcentral.com/articles/10.1186/s13756-017-0232-x

9. Cosgrove SE, Qi Y, Kaye KS, Harbarth S, Karchmer AW, Carmeli Y. The impact of methicillin resistance in Staphylococcus aureus bacteraemia on patient outcomes: mortality, length of stay, and hospital charges. Infect Control Hosp Epidemiol 2005; 26:166–74. Available at: http://www.ncbi.nlm.nih.gov/pubmed/15756888

Oral Antibiotic Prescribing in Healthcare-associated Pneumonia Patients at Hospital Discharge

To the Editor—We read with interest the article by Vaughn et al [1] reporting increases in fluorquinolone (FQ) prescribing at discharge in Michigan hospitals with antimicrobial stewardship programs targeting FQ use. We applaud the authors’ efforts in quantifying the discordance in FQ use between the inpatient setting and at hospital discharge. This study highlights the critical need for stewardship interventions at discharge prescribing, a critical step in the hospital antimicrobial-use process [2].

Given the observed percentage of FQs prescribed at discharge in the study, we agree with the authors’ discussion points that stewardship interventions should recommend alternative, narrow-spectrum antibiotics at discharge. However, in their analysis of non-intensive care patients, approximately 35% of pneumonia patients were classified as having healthcare-associated pneumonia (HCAP) and 86.6% of pneumonia patients who were prescribed a FQ received levofloxacin [1]. Since more than 40% of patients are unable to produce sputum or produce it in a timely manner [3, 4], many patients are treated empirically and have no microbiological diagnosis. Thus, we speculate that it may prove challenging for stewardship programs to recommend a narrow-spectrum nonpseudomonal oral regimen to a prescriber who has observed his or her HCAP patient clinically improving on empiric broad-spectrum intravenous antibiotics. This is an issue that has been observed at our institutions and has been documented by Madaras-Kelly et al [5], who found respiratory tract culture availability to be more associated with de-escalation in the inpatient setting but de-escalation still uncommon despite Pseudomonas aeruginosa (PsA) and methicillin-resistant Staphylococcus aureus not being identified in cultures.

The HCAP designation was not included in the 2016 Infectious Diseases Society of America and the American Thoracic Society hospital-acquired and ventilator-associated pneumonia guidelines. However, a separate entity or some modification of HCAP may be included in the next version of the community-acquired pneumonia guidelines [6]. It remains to be seen what criteria this upcoming guideline will acknowledge as a risk factor for multidrug-resistant pathogens such as PsA. This may well impact the number of